Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?

被引：18

作者：

Polo, V. ^{[1
,2
]}

Besse, B. ^{[1
]}

机构：

[1] Gustave Roussy, Dept Canc Med, F-94805 Villejuif, France

[2] Ist Oncol Veneto IRCCS, Dept Med Oncol 2, Padua, Italy

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 07期

关键词：

non-small-cell lung cancer; continuation maintenance; switch maintenance; early second line; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; PLATINUM-BASED CHEMOTHERAPY; DOUBLE-BLIND; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; SUPPORTIVE CARE; PEMETREXED PLUS; OPEN-LABEL; CARBOPLATIN;

D O I：

10.1093/annonc/mdt529

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Four to six cycles of platinum-based chemotherapy are currently recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus, progression-free and overall survival with minimal toxicity and maintenance or improvement of quality of life of patients. We review here clinical trials evaluating continuation maintenance therapy or switch maintenance therapy in locally advanced or metastatic NSCLC, to highlight the achievements made and critical issues faced. Based on the available results and limitations of these trials, maintenance therapy should be considered a good treatment strategy for a limited subgroup of patients. Maintenance therapy should be personalised according to the characteristics of patients and their disease, taking into account the data available for the agents used in this setting.

引用

页码：1283 / 1293

页数：11

共 52 条

[31] Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer [J].

Perol, Maurice ;

Chouaid, Christos ;

Perol, David ;

Barlesi, Fabrice ;

Gervais, Radj ;

Westeel, Virginie ;

Crequit, Jacky ;

Lena, Herve ;

Vergnenegre, Alain ;

Zalcman, Gerard ;

Monnet, Isabelle ;

Le Caer, Herve ;

Fournel, Pierre ;

Falchero, Lionel ;

Poudenx, Michel ;

Vaylet, Fabien ;

Segura-Ferlay, Celine ;

Devouassoux-Shisheboran, Mojgan ;

Taron, Miquel ;

Milleron, Bernard .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3516-3524

[32] Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Peters, S. ;

Adjei, A. A. ;

Gridelli, C. ;

Reck, M. ;

Kerr, K. ;

Felip, E. .

ANNALS OF ONCOLOGY, 2012, 23 :56-64

[33] American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 [J].

Pfister, DG ;

Johnson, DH ;

Azzoli, CG ;

Sause, W ;

Smith, TJ ;

Baker, S ;

Olak, J ;

Stover, D ;

Strawn, JR ;

Turrisi, AT ;

Somerfield, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :330-353

[34] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial [J].

Pirker, Robert ;

Pereira, Jose R. ;

Szczesna, Aleksandra ;

von Pawel, Joachim ;

Krzakowski, Maciej ;

Ramlau, Rodryg ;

Vynnychenko, Ihor ;

Park, Keunchil ;

Yu, Chih-Teng ;

Ganul, Valentyn ;

Roh, Jae-Kyung ;

Bajetta, Emilio ;

O'Byrne, Kenneth ;

de Marinis, Filippo ;

Eberhardt, Wilfried ;

Goddemeier, Thomas ;

Emig, Michael ;

Gatzemeier, Ulrich ;

Pirker, R. ;

Thatcher, N. ;

Armand, J. P. ;

Camus, P. ;

Victor, N. ;

Emig, M. ;

Mueser, M. ;

Pilz, K. ;

Goddemeier, T. ;

Montaner, I. ;

Lachs, Martin ;

Hoang-Sayag, Loan ;

Alvarez, A. ;

Coppola, F. ;

Recondo, G. ;

Richardet, E. ;

Kirsten, F. ;

Karapetis, C. ;

Parente, P. ;

Michael, M. ;

White, S. ;

Boyce, A. ;

Lewis, C. ;

Slancar, M. ;

Pavlakis, N. ;

Abdi, E. ;

Underhill, C. ;

Pittman, K. ;

Burghuber, O. ;

Pirker, R. ;

Ruckser, R. ;

Ulsperger, E. .

LANCET, 2009, 373 (9674) :1525-1531

[35] Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) [J].

Reck, M. ;

von Pawel, J. ;

Zatloukal, P. ;

Ramlau, R. ;

Gorbounova, V. ;

Hirsh, V. ;

Leighl, N. ;

Mezger, J. ;

Archer, V. ;

Moore, N. ;

Manegold, C. .

ANNALS OF ONCOLOGY, 2010, 21 (09) :1804-1809

[36] Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL [J].

Reck, Martin ;

von Pawel, Joachim ;

Zatloukal, Petr ;

Ramlau, Rodryg ;

Gorbounova, Vera ;

Hirsh, Vera ;

Leighl, Natasha ;

Mezger, Joerg ;

Archer, Venice ;

Moore, Nicola ;

Manegold, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1227-1234

[37]

Rittmeyer A, 2013, J CLIN ONCOL S, V31, P8014

[38] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[39] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[40] Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer [J].

Scagliotti, Giorgio ;

Novello, Silvia ;

von Pawel, Joachim ;

Reck, Martin ;

Pereira, Jose Rodrigues ;

Thomas, Michael ;

Abrao Miziara, Jose Elias ;

Balint, Beatrix ;

De Marinis, Filippo ;

Keller, Alan ;

Aren, Osvaldo ;

Csollak, Maria ;

Albert, Istvan ;

Henrique Barrios, Carlos ;

Grossi, Francesco ;

Krzakowski, Maciej ;

Cupit, Lisa ;

Cihon, Frank ;

DiMatteo, Sandra ;

Hanna, Nasser .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1835-1842

← 1 2 3 4 5 6 →